Researchers compared medical records of about 1,200 adults with AML who got BMT between 2008 and 2015. One group of people got haplo BMT. The other group of people got fully matched BMT. Both groups got medicine to prevent graft-versus-host disease (GVHD), a serious complication of BMT.
Three years after transplant, both groups lived equally long. However, the group with haplo BMT had a lower risk of chronic GVHD than the group with fully matched BMT.
Currently, it can be hard to find fully matched donors for people who are not white. In this study, about 1 in 5 people who got haplo BMT were black, compared to 1 in 20 people who got a fully matched BMT. While the donor registry needs more people from all ethnic backgrounds, this research shows that haplo BMT can help more people access treatment.
More research is needed on haplo BMT.